Clinical Pharmacology Characterization of the First‐In‐Class Oncolytic Viral Therapy T‐VEC in Adults and Pediatric Subjects.

Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T‐VEC) is a first‐in‐class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T‐VEC that supported the development of...

Full description

Bibliographic Details

Published in:	Journal of Clinical Pharmacology Vol. 66; no. 1; pp. 1 - 14
Main Authors:	Zhang, Xinwen, Balu, Bhavya, Chen, Po‐Wei, Mehta, Khamir, Li, Chuang, Upreti, Vijay V.
Format:	pictorial research tables/charts Journal Article
Published:	Wiley-Blackwell Jan2026
Online Access:	View this record in EBSCOhost